U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining more than 150 points on Wednesday.The Dow traded down 0.17% to 49,380.41 while the NASDAQ gained 0.71% to 23,714.14. The S&P 500 also rose, gaining, 0.27% to 6,963.78.Check This Out: Top 2 Materials Stocks That May Implode In JanuaryLeading and Lagging SectorsHealth care shares gained by 1.1% on Wednesday.In trading on Wednesday, materials stocks dipped by 1.5%.Top HeadlineThe ISM services PMI rose for a third straight month ...

Media ReleaseCOPENHAGEN, Denmark; January 07, 2026 Supports Genmab’s ambition to build an AI-enabled innovation model that advances the company’s vision of bringing transformative antibody medicines to patients Genmab A/S (Nasdaq: GMAB) announced today a partnership with Anthropic to advance and enhance the company’s research and development (R&D) processes through the adoption of cutting-edge artificial intelligence (AI) capabilities. Under the agreement, Genmab and Anthropic will design and deploy custo ...

Core Viewpoint - Rigel Pharmaceuticals, Inc. will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, highlighting its focus on hematologic disorders and cancer [1]. Company Overview - Rigel Pharmaceuticals, Inc. is a biotechnology company established in 1996, based in South San Francisco, California, dedicated to discovering and developing novel therapies for patients with hematologic disorders and cancer [3]. - The company is publicly traded on Nasdaq under the ticker symbol RIGL [3]. Event Details - The presentation will be led by Raul Rodriguez, the president and CEO of Rigel Pharmaceuticals, scheduled for 3:00 p.m. PT (6:00 p.m. ET) [1]. - Investors can access the live webcast or archived recording through the Investor Relations section of Rigel's website [2].

Core Insights - AI is increasingly influencing healthcare by empowering patients to navigate complex health systems, moving beyond traditional professional and institutional roles [1][2] Usage Trends - Over 5% of all ChatGPT messages globally are health-related, with more than 40 million health-related prompts submitted daily; in the US, about one in four regular users ask health questions weekly [3] - Most health-related inquiries are not diagnostic; users seek assistance in interpreting medical information, preparing for appointments, understanding insurance, and managing administrative tasks [4] Health Insurance Focus - Health insurance is a significant theme, with an estimated 1.6 to 1.9 million ChatGPT messages weekly focused on comparing plans, understanding pricing, and navigating claims and billing [5] Timing of Usage - Approximately 70% of health-related conversations occur outside normal clinic hours, indicating that AI serves as a first-line information source when traditional care is unavailable [6] Geographic Disparities - Users in underserved rural areas generate nearly 600,000 healthcare-related messages weekly, particularly in "hospital deserts" where access to medical facilities is limited [7] AI's Role in Patient Support - While AI cannot replace closed hospitals or specialist services, it aids patients in interpreting symptoms and organizing information, potentially improving patient engagement with clinicians [8] Self-Advocacy - Case studies show patients using AI to advocate for themselves, such as compiling literature for insurance appeals or identifying medication interactions [9][10] Professional Adoption - About two-thirds of US physicians used AI for at least one task in 2024, a significant increase from the previous year; nurses and pharmacists also utilize AI for documentation and workflow support [11] Diagnostic Limitations - Diagnostic use of AI remains limited, suggesting its near-term value lies in enhancing efficiency and support rather than replacing clinical judgment [12] Investment Implications - The report indicates that AI in healthcare encompasses various sectors, including infrastructure, software, and consumer-level tools, highlighting a shift towards more distributed adoption among patients [13]

Core Insights - Evaxion A/S is a clinical-stage TechBio company focused on developing AI-Immunology™ powered vaccines and will present its 2026 milestones at the Biotech Showcase conference in San Francisco from January 12-14, 2026 [1][2] - The company aims to engage with stakeholders and potential business partners during the conference week [2] Company Overview - Evaxion utilizes its proprietary AI platform, AI-Immunology™, to decode the human immune system and create novel immunotherapies for cancer, bacterial diseases, and viral infections [3] - The company has developed a clinical-stage oncology pipeline of personalized vaccines and a preclinical pipeline targeting infectious diseases with significant unmet medical needs [3] - Evaxion is dedicated to transforming patient care through innovative and targeted treatment options [3] Presentation Details - The presentation by CEO Helen Tayton-Martin is scheduled for January 13, 2026, at 2:00 PM PST/11:00 PM CET in the Yosemite C track [3] - Contact information for investor relations is provided for further inquiries [3]

The listing on one of the world’s largest global cryptocurrency exchanges expands market access and secondary liquidity for Enlivex’s primary digital treasury asset Nes-Ziona, Israel, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”) today reported that its treasury asset, the RAIN token, has been listed on the KuCoin cryptocurrency exchange effective January 6, 2026, expanding access to the token across a major global digital asset trading platform. KuC ...

Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, with 381 patients randomized or approved to randomize as of January 6, 20264D-150 PRISM wet AMD 2-year Phase 2b data expected mid-20264D-150 DME global Phase 3 trial initiation expected Q3 2026; 2-year SPECTRA Phase 1/2 data expected H2 2026Appointed Glenn Sblendorio to Board of Directors, adding deep commercial and operating experience, including in retina therapeu ...

CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Executive Officer of Prime Medicine, will present a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 9:00 a.m. PT (12:00 p.m. ET) in San Francisco, California. A live audio webcast of the presentation wil ...

Applied Digital ( APLD ) stock has seen quite the upward trend in recent times. Towards the latter half of 2025, around mid-October, shares reached the $37 mark. Now, shares have come down quite a bit and can be picked up in the $30 range after theI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific founda ...

Group 1 - Redwire Corporation (RDW) and other small-cap space/defense companies have experienced a bullish run-up over the past month, indicating a need for significant momentum in the sector [1] - The article emphasizes the importance of evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and potential market opportunities in the biotech sector [1] - The focus is on identifying promising biotechnology companies that are innovating through novel mechanisms of action, first-in-class therapies, or platform technologies [1] Group 2 - The author aims to deliver research that is both technically sound and investment-driven, combining scientific expertise with financial and market analysis [1] - The article highlights the dynamic and rapidly evolving nature of the biotech sector, where breakthrough science can lead to outsized returns [1]